- PR Newswire•13 hours ago
ALBANY, N.Y., Aug. 23, 2016 /PRNewswire/ -- AMRI (AMRI) today announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology and has completed several projects for its customers. The company will continue to use the technology to enhance its drug discovery service offerings and internal research and development. "While many people know CRISPR for its potential to edit defective genes to cure disease, there are a range of other applications in drug discovery for which CRISPR has significant utility that are critical to our customers' R&D projects, notably drug target assessment and in vitro model development for lead discovery and optimization," said Christopher Conway, Senior Vice President, Discovery and Development Services at AMRI.
- GlobeNewswire•19 hours agoUpdate in Lawsuit for Investors in Albany Molecular Research, Inc. shares announced by Shareholders Foundation
SAN DIEGO, Aug. 23, 2016-- The Shareholders Foundation, Inc. announces that a lawsuit is pending in New York on behalf of certain purchasers of shares of Albany Molecular Research, Inc. over alleged Securities ...
- PR Newswire•13 days ago
WAYNE, Pa., Aug. 10, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Albany Molecular Research, Inc. ("Albany Molecular" or the ...
Albany Molecular Research Inc. (AMRI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||14.00 x 100|
|Ask||16.90 x 200|
|Day's Range||14.70 - 15.00|
|52wk Range||12.45 - 21.69|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-15.13|
|Avg Vol (3m)||256,553|
|Dividend & Yield||N/A (N/A)|